Sucralfate NDC 0713-0791

NDC codes

FDA NDC Directory

Product NDC (as listed)0713-0791Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00713-0791Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0713-0791-75	00713079175	420 mL in 1 BOTTLE (0713-0791-75)Marketed from Dec 19, 2024

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate
Active ingredients: Sucralfate — 1 g/10mL
Dosage form: Suspension
Route: Oral
Labeler: Cosette Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217126
Marketing start: Dec 19, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 0713-0791_27c19a55-ceb8-91c3-e063-6394a90a726eSPL ID 27c19a55-ceb8-91c3-e063-6394a90a726eSPL set ID 3054ce94-78a2-4da4-8b14-95311b412ab2RxCUI 313123UNII XX73205DH5UPC 0307130791755
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400713079175 followed by a unit qualifier and the quantity

Package 00713-0791-75. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 25, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217126

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217126
Product	Strength	Form · route	Labeler	Product NDC
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	Safecor Health, LLC	48433-226